Merck Ebola vaccine Ervebo shown to offer substantial protection
Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had been vaccinated at least 10 days before being exposed to the virus, a new study reports. An earlier study had shown that people who were vaccinated but went on to develop the disease were more likely to survive the infection.
The analysis, published Tuesday in the journal Lancet Infectious Diseases, offers the first peer-reviewed assessment of how well the vaccine, Ervebo, works in a challenging real-world setting.
Read Original Article: Merck Ebola vaccine Ervebo shown to offer substantial protection »
